Thermal Shift Assay for Drug Resistance Biomarker Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for monitoring biochemical processes and drug action within the tumor environment, limiting the development of effective cancer therapies due to challenges in accessing and understanding biochemical changes and drug resistance mechanisms.
Innovation Solution
A thermal shift assay method is developed to identify candidate biochemical biomarkers for drug resistance by analyzing protein melting temperatures in samples from drug-responsive and non-responsive patients, allowing for the differentiation of protein activation states and the identification of proteins with different melting temperatures as potential biomarkers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional broadly cytotoxic drugs are used for cancer therapy, then treatment coverage is broad, but therapeutic efficacy is limited and drug resistance develops
Solution Approach 1:
The patent uses thermal shift assay to detect changes in protein melting temperatures, which reflect biochemical parameter changes in response to drug treatment. This enables identification of proteins whose thermal stability changes indicate drug response or resistance, allowing for personalized therapy adjustment based on measured parameter changes rather than broad cytotoxicity
Solution Approach 2:
The patent replaces conventional cytotoxic mechanical/chemical killing mechanisms with a diagnostic approach that uses thermal denaturation principles to detect protein conformational changes. By substituting direct therapeutic mechanical action with thermal analysis for detection, the system can identify resistance mechanisms and guide more effective targeted therapies
2Loss of information
If next generation sequencing is used to map driver mutations, then genome-level understanding is achieved, but biochemical process monitoring is insufficient
Solution Approach 1:
The patent uses thermal shift assay as an intermediary method that bridges genomic information and biochemical function. By measuring protein melting temperatures, the assay provides a functional readout of protein state that connects genomic mutations to actual biochemical behavior and drug response, filling the information gap between sequence data and functional outcome
Solution Approach 2:
The patent detects biochemical process changes by measuring parameter changes in protein thermal stability. The melting temperature shifts serve as measurable parameters that reflect underlying biochemical process changes, making invisible biochemical states detectable through thermal denaturation transitions
3Reliability
If targeted therapies are developed based on molecular understanding, then cancer specificity is improved, but drug response variability increases
Solution Approach 1:
The patent implements a feedback mechanism where thermal shift assay results from patient samples provide information about actual protein states and drug responses. This feedback loop allows clinicians to adjust targeted therapy based on measured biochemical responses, improving prediction accuracy by incorporating real patient data rather than relying solely on pre-treatment molecular profiling
Solution Approach 2:
The patent measures actual biochemical parameter changes in patient responses to targeted therapy using thermal shift assay. By quantifying protein melting temperature changes in response to treatment, the system provides precise measurement of drug effect at the biochemical level, enabling better prediction and personalization of therapeutic outcomes
4Quantity of substance
If thermal shift assay is performed on patient samples, then proteome-wide analysis is achieved, but sample processing complexity increases
Solution Approach 1:
The patent employs a universal thermal shift assay platform that can analyze multiple proteins across the proteome using the same basic methodology. The thermal denaturation principle applies universally to all proteins, allowing proteome-wide analysis with a single approach rather than requiring different methods for different protein targets, thereby managing complexity through methodological universality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the accurate assessment of biochemistry and identification of candidate biomarkers for drug resistance, providing a proteome-wide analysis that can be performed directly on patient samples, potentially improving cancer therapy strategies by predicting drug response and resistance.
Implementation Method 1
heating a sample from a patient treated with the drug and responsive to the drug and a sample from a patient treated with the drug but with a reduced response to the drug, analysing the products to determine the melting temperatures of at least one protein in each sample
Data Source
AI summary
The present invention concerns a method for identifying and using a biomarker, or creating a proteome profile, indicative of a reduced response to a drug in a patient involving a thermal shift assay on a sample. The method comprises the steps of a) heating a sample from a patient b) separating soluble from insoluble protein, c) analysing either or both the soluble and insoluble protein fractions of step b) to determine the melting temperature.